Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023)

Historic Gains from Sales and Divestitures for Cytek Biosciences (CTKB) over the last 2 years, with Q2 2023 value amounting to $260297.0.

  • Cytek Biosciences' Gains from Sales and Divestitures rose 23809.2% to $260297.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $260297.0, marking a year-over-year increase of 23809.2%. This contributed to the annual value of $215433.0 for FY2022, which is N/A changed from last year.
  • As of Q2 2023, Cytek Biosciences' Gains from Sales and Divestitures stood at $260297.0, which was up 23809.2% from $81639.0 recorded in Q1 2023.
  • Over the past 5 years, Cytek Biosciences' Gains from Sales and Divestitures peaked at $260297.0 during Q2 2023, and registered a low of $76990.0 during Q2 2022.